Claudia Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Claudia Rodriguez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Albert J. Farias
Keck School of Medicine of the University of Southern California, Los Angeles, CA
4 shared publications - Alberto Carvajal
Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
4 shared publications - Angel Arizpe
Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
4 shared publications - Carol Y. Ochoa-Dominguez
Center for Health Equity Education and Research University of California San Diego California USA
4 shared publications - Claudia M. Toledo-Corral
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Health Sciences, California State University, Northridge, Northridge, CA, USA
4 shared publications - Katelyn Queen
Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California
4 shared publications
Latest Publications
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Supplementary Table 1: Shows the distribution of cancer survivors excluded compared to those included in our final sample by all study variables
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Supplementary Table 1: Shows the distribution of cancer survivors excluded compared to those included in our final sample by all study variables
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Data from Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Background:Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex.Methods:Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors.Results:In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences.Conclusions:Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities.Impact:The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Background:Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex.Methods:Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors.Results:In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences.Conclusions:Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities.Impact:The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Supplementary Table 2: Exploration of missing outcome data by exposure variables
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Supplementary Table 2: Exploration of missing outcome data by exposure variables
- 11 November 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (1) , 51-58
Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Background: Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex. Methods: Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors. Results: In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences. Conclusions: Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities. Impact: The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.
- 11 November 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (1) , 51-58
Alcohol and Cannabis Use Associated with Cardiometabolic Biomarkers among “All of Us” Cancer Survivors
Background: Cancer survivors are at increased risk for cardiometabolic comorbidities following cancer treatment, which may be further exacerbated by cannabis and alcohol use. We aimed to examine the direct relationships of cannabis, alcohol, and the co-use of both substances with cardiometabolic risk factors and to explore disparities by race/ethnicity and sex. Methods: Cross-sectional data were extracted from adult cancer survivors in the “All of Us” from 2018 to 2022. Cannabis use was defined as occasional or frequent/regular cannabis use (vs. never) in the past 3 months and hazardous alcohol intake (AUDIT-C >3 for females; AUDIT-C >4 for males) versus nonhazardous in the past year, respectively. Co-use was defined as participants who engaged in regular cannabis and hazardous alcohol intake. We identified binary cardiovascular, immune, and metabolic system biomarkers, with high values defined by clinically established cutoffs or >75th percentile. We used multivariable logistic regression adjusting for sociodemographic and clinical factors. Results: In our sample (N = 7,054), 7.6% were Hispanic, 6.2% were Black, and 86.2% were White cancer survivors. Less than 5% of Hispanic and White survivors reported substance co-use compared with 7% of Black survivors. Compared with never-users, co-users were 1.58 (95% confidence interval, 1.14–2.19) more likely to have high blood pressure. No significant associations were found between co-use and immune biomarkers or sex differences. Conclusions: Co-use of cannabis and hazardous alcohol may worsen high blood pressure in survivors, who are at higher risk for cardiometabolic comorbidities. Impact: The study investigates substance use and cardiometabolic biomarkers, urging much research on their effects on cancer survivors.